MX69

Research use only, not for human use.

A novel specific inhibitor of MDM2 inhibitor with Kd of 2.75 uM.

A novel specific inhibitor of MDM2 inhibitor with Kd of 2.75 uM; induces ubiquitination of endogenous MDM2, results in activation of p53 and inhibition of XIAP, and induces cell apoptosis and death in cancer cells; shows significant apoptotic and anti-proliferative effects on MDM2-expressing cancer cells both in vitro and in vivo, with minimal inhibitory effect on normal human hematopoiesis.

MX69 blocks the MDM2 protein-XIAP RNA interaction, leading to MDM2 degradation. MX69 shows minimal inhibitory effect on normal human hematopoiesis in vitro and is very well tolerated in animal models. MX69-induced MDM2 down regulation results not only in inhibition of XIAP expression, but also in activation of p53, which contributes to cancer cell apoptosis in vitro.

MX69-induced MDM2 downregulation results in activation of p53 which contributes to inhibition of cancer cell proliferation in vivo.

MX 69 | MX-69

Apoptosis

MDM2-p53

Mdm2

Cancer

——

1005264-47-0

474.57134

C27H26N2O4S

>98% (HPLC)

DMSO: ≥ 30 mg/mL

O=S(C1=CC2=C(NC(C3=CC=C(C(O)=O)C=C3)C4C2C=CC4)C=C1)(NC5=C(C)C(C)=CC=C5)=O

4-{8-[(3,4-Dimethylphenyl)sulfamoyl]-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinolin-4-yl}benzoic acid

(-20℃)

With Ice Pack

≥ 2 years